Varun Saxena, Jennifer C. Lai, Jacqueline G. O'Leary, Elizabeth C. Verna, Robert S. Brown, R. Todd Stravitz, James F. Trotter, Kartik Krishnan, Norah A. Terrault, for the Consortium to Study Health Outcomes in HCV Liver Transplant Recipients – 5 December 2011 – African American (AA) recipient‐donor race mismatch has been associated with graft loss and mortality, but studies of an association between race mismatch and hepatitis C virus (HCV) disease severity are lacking.

Wojciech Rudzinski, Alfonso H. Waller, Amit Prasad, Sunita Sood, Christine Gerula, Arun Samanta, Baburao Koneru, Marc Klapholz – 5 December 2011 – The inability to achieve 85% of the maximum predicted heart rate (MPHR) on dobutamine stress echocardiography (DSE) is defined as chronotropic incompetence and is a predictor of major cardiac events after orthotopic liver transplantation (OLT). The majority of patients with end‐stage liver disease (ESLD) receive beta‐blockers for the prevention of variceal bleeding.

Anton I. Skaro, Edward Wang, Vadim Lyuksemburg, Michael Abecassis – 5 December 2011

Yue Yu, James E. Fisher, Joseph B. Lillegard, Brian Rodysill, Bruce Amiot, Scott L. Nyberg – 5 December 2011 – Cell therapies, which include bioartificial liver support and hepatocyte transplantation, have emerged as potential treatments for a variety of liver diseases. Acute liver failure, acute‐on‐chronic liver failure, and inherited metabolic liver diseases are examples of liver diseases that have been successfully treated with cell therapies at centers around the world.

Josh Levitsky, Olaf Guckelberger – 5 December 2011 – The International Liver Transplantation Society held its yearly meeting as a joint conference with the European Liver and Intestine Transplant Association and the Liver Intensive Care Group of Europe at the Valencia Congress Center (Valencia, Spain) from June 22 to 25, 2011.

Basant Mahadevappa, Ganesh Gunasekaran, Sunu John Philip, Caroline Rochon, Patricia Sheiner – 5 December 2011

Chakri Panjala, Justin H. Nguyen, Ali N. Al‐Hajjaj, Barry A. Rosser, Raouf E. Nakhleh, Mellena D. Bridges, Stephen J. Ko, Steven J. Buskirk, George P. Kim, Denise M. Harnois – 5 December 2011 – The very early experience with liver transplantation (LT) for cholangiocarcinoma (CC) was dismal because of the poor survival outcomes and the high recurrence rates. However, LT for CC in conjunction with neoadjuvant chemoradiation recently has shown encouraging results, although the data are extremely limited.

Shin Hwang, Tae‐Yong Ha, Chul‐Soo Ahn, Deok‐Bog Moon, Ki‐Hun Kim, Gi‐Won Song, Dong‐Hwan Jung, Gil‐Chun Park, Jung‐Man Namgoong, Sung‐Won Jung, Sam‐Youl Yoon, Kyu‐Bo Sung, Gi‐Young Ko, Byungchul Cho, Kyoung Won Kim, Sung‐Gyu Lee – 5 December 2011 – Because revascularization of the inferior right hepatic vein (IRHV) is a major component of right liver graft (RLG) reconstruction, we assessed the surgical techniques and clinical outcomes of IRHV reconstruction so that we could formulate practical guidelines for standardized procedures.

Ashley N. Bedel, Trina S. Hemmelgarn, Rohit Kohli – 5 December 2011 – Cytomegalovirus (CMV) is the most common viral infection after solid organ transplantation (SOT). Safe and effective prophylactic regimens that decrease its incidence after SOT are essential for long‐term graft survival. Although valganciclovir is not Food and Drug Administration–approved for CMV prophylaxis in liver transplant recipients, postmarketing studies have shown valganciclovir to be as effective as ganciclovir in high‐risk adult patients undergoing SOT.

Mazen Albeldawi, Ashish Aggarwal, Surabhi Madhwal, Jacek Cywinski, Rocio Lopez, Bijan Eghtesad, Nizar N. Zein – 5 December 2011 – As survival after orthotopic liver transplantation (OLT) improves, cardiovascular (CV) disease has emerged as the leading cause of non–graft‐related deaths. The aims of our study were to determine the cumulative risk of CV events after OLT and to analyze predictive risk factors for those experiencing a CV event after OLT. We identified all adult patients who underwent OLT at our institution for end‐stage liver disease between October 1996 and July 2008.